GLG News by Lung Cancer Oncologists (US)

January 29, 2008
Roche Holding AG : Avastin in the EU receives approval for wider applicability

Analysis of: Roche's Avastin Cleared For Wider Use in the EU (online.wsj.com)

Avastin was approved for wider use in the EU with multiple chem agents including Roche's Xeloda (Can you say synergy?)

January 28, 2008
Boehringer Ingelheim today announced that the Committee for Medicinal Products in Human Use (CHMP) of the European Medicines Agency has issued a positive opinion to recommend marketing authorisation of their novel, oral direct thrombin inhibitor, dabigatran etexilate. May well replace current agents!

By a GLG Expert Contributor

Analysis of: European Medicines Agency recommends approval of novel oral anticoagulant, dabigatran etexilate (www.pipelinereview.com)

An Oral agent that can be used as an alternative to the cumbersome Warfarin as well as low molecular weight heparin.

January 28, 2008
Drug reps: a double edged sword?

By a GLG Expert Contributor

Analysis of: 19 Percent of Office-Based Physicians Refuse to See Pharmaceutical, Biotech and Medical Device Sales Reps (www.drugs.com)

Physicians are seeing less and less of pharmaceutical company reps due to personal as well as institutional restrictions.

January 25, 2008
Amgen's prospects?? +/-?

By a GLG Expert Contributor

Analysis of: Amgen Shows Little Growth (online.wsj.com)

A monoclonal antibody may "rescue" Amgen from the fall off in erythropoietin use.

January 24, 2008
XL139: BMS gamble??

By a GLG Expert Contributor

Analysis of: Exelixis and Bristol-Myers Squibb to Co-Develop XL139, an Inhibitor of the Hedgehog Pathway (www.prnewswire.com)

BMS is basically taking a flyer that this new targeting agent will be clinically efficacious.

January 21, 2008
ARIAD Pharmaceutical's Deforolimus: mTOR inhibition revisited

By a GLG Expert Contributor

Analysis of: Phase I Trial of the Novel Mammalian Target of Rapamycin Inhibitor Deforolimus (AP23573; MK-8669) Administered Intravenously Daily for 5 Days Every 2 Weeks to Patients With Advanced Malignancies (jco.ascopubs.org)

Deforolimus is an analog of rapamycin that has been shown to inhibit mTOR activity. This is only a phase I trial and is rather dated but still points to potential efficacy. The editorial in the JCO http://jco.ascopubs.org/cgi/content/full/26/3/348 points to the hopes and future for this...

January 18, 2008
Rituxan: A slightly new twist. Beneficial to who??

By a GLG Expert Contributor

Analysis of: Rituximab Combined with CHOP Improves Survival in Older Lymphoma Patients (www.medscape.com)

Rituxan added to CHOP chemo in aggressive NHL and given at 2 week rather than 3 week intervals is as effective and safe as the standard Q 3 week program in older (61-80) patients

January 17, 2008
Prostate cancer: Will it be used? Yes!! Will the insurers pay for early detection??

By a GLG Expert Contributor

Analysis of: $300 to Learn Risk of Cancer of the Prostate (www.nytimes.com)

We can now determine with genetic tests who is at risk for developing PC. ProActive Genetics. The more genetic variants found, the greater the risk of PC. 4 or 5 variants increased ones risk x 4.5.

January 17, 2008
Vidaza use in the EU. I'm surprised it wasn't already in use.

By a GLG Expert Contributor

Analysis of: Pharmion Submits European Marketing Authorization Application (MAA) For Vidaza(R) In Patients With Higher Risk Myelodysplastic Syndromes (MDS) (www.medicalnewstoday.com)

Pharmion's Vidaza is seeking approval for use in higher risk myelodysplasia (MDS) in the EU.

January 15, 2008
Neuropilin-2 : An interesting class of agents

By a GLG Expert Contributor

Analysis of: Neuropilin-2 May Offer New Therapeutic Target in Colon Cancer (www.medscape.com)

Targeting this protein MAY offer a therapeutic alternative or "add on" in GI malignancies.

Previous Page : 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 Next181 to 190 of 457

GLG News by Lung Cancer Oncologists (US)

Most Popular Healthcare News